More clinical data on protease inhibitors.

Clinical information from Abbott Laboratories, Merck, Hoffman-LaRoche, and Agouron is provided on the following protease inhibitors: ritonavir, indinavir sulfate (Crixivan), saquinavir, and Viracept. Overall, the research presented suggests that higher doses of these drugs, and combinations with nucleoside analogs, appear to produce more potent and durable antiviral effects than seen in earlier protease inhibitor studies. An update is included on protease inhibitor compassionate use programs on indinavir, saquinavir, and Viracept; as well as a list of protease drug interactions for ritonavir and indinavir.